Novo Nordisk A/S (NVO) Shares Drop on U.S. Scrutiny of Insulin Drug
10/26/2012 6:09:02 AM
Novo Nordisk A/S | Jobs at Novo Nordisk A/S
Shares in Denmark's Novo Nordisk fell as much as 5 percent on Friday, after a U.S. expert panel assessing the group's ultra long-acting insulin degludec said it will study the cardiovascular safety of the drug.
The statement late on Thursday raised a potential obstacle to approval of the drug, which Novo plans to market under the brand name Tresiba, in the world's top market ahead of the panel's meeting on November 8.